Prolotherapy and corticosteroid injection in plantar fasciitis

Not Applicable

Recruiting

• Conditions: Plantar fasciitis.; Other soft tissue disorders; M70-M79

• Registration Number: IRCT20210305050582N1
• Lead Sponsor: Shiraz University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 26 April 2021

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 44

Inclusion Criteria

Patients with plantar fasciitis.
No analgesic using during the study.
Over 18 years of age.

Exclusion Criteria

Patients with ankylosing spondylitis.
Patients with Reiter's syndrome.
Patients with rheumatoid arthritis.
Patients with gout disease.
Anatomical disturbance in the site of the lesion.
Drug sensitivity to corticosteroids or lidocaine.
Any local injection for plantar fasciitis within the past 6 months (including corticosteroid, platelet rich plasma, prolotherapy and lidocaine).
Known coagulopathy.
Pregnancy or lactation.

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The patients' reported pain score based on visual analog scale (VAS). Timepoint: Before the intervention, first month and third month. Method of measurement: Patients will quantify their pain by VAS using the numbers 1; for the least severity; to 10; for the most severity; of he pain.;The foot function index (FFI). Timepoint: Before the intervention, first month and third month. Method of measurement: Standard FFI questionnaire.